CurrentNeighborhood Health Plan of Rhode IslandPolicy 1975-A 12-2022

Acamprosate prior authorization for alcohol use disorder

Defines prior authorization requirements for acamprosate calcium delayed-release tablets for treatment of alcohol use disorder and the clinical conditions under which the drug is covered. Affects prescribers seeking formulary coverage through Neighborhood Health Plan (CVS Caremark criteria).

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyAcamprosate prior authorization for alcohol use disorder

Policy CodePolicy 1975-A 12-2022

Change TypeNo material change

Effective Date

Next Review Date

Key ActionSubmit prior authorization showing DSM-5 diagnosis of alcohol use disorder and documentation that the patient is abstinent at treatment initiation and enrolled in psychosocial support.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

FDA-approved indicationmaintenance of abstinence

DSM-5diagnosis requirement

Psychosocial supportcomprehensive care

Requiredabstinence at start

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage criteria

Covered when the following are met:

Primary coverage requirements: The patient has a diagnosis of alcohol use disorder as defined by DSM-5 AND the requested drug will be used as part of a comprehensive management program that includes psychosocial support AND the patient is abstinent from alcohol at treatment initiation.

From coverage criteria and FDA-approved indications

Continuation/restart criteria: The request is for continuation of therapy with demonstrated positive clinical response (e.g., abstinence from alcohol; increase in abstinent days, decrease in heavy drinking episodes, improved physical health, improvements in psychosocial functioning) OR the patient experienced improvement on prior therapy and the requested drug will be restarted due to relapse.

Continuation and restart conditions listed in policy

Efficacy for acamprosate has specific prerequisites: clinical trials and the FDA label note that its benefit in promoting abstinence has not been demonstrated in patients who have not undergone detoxification or who are not abstinent at treatment initiation. This policy therefore requires that patients be abstinent from alcohol at the start of therapy in order to meet coverage criteria.

Treatment with acamprosate must be delivered as part of a broader care plan; the FDA states the medication should be used within a comprehensive management program that includes psychosocial support. Requests lacking documentation that the medication will be combined with appropriate psychosocial interventions or that the patient was abstinent at initiation are at greater risk for denial.

Provider Actions & Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required before coverage of acamprosate (acamprosate calcium). Requests must document the diagnosis and that treatment will be part of a comprehensive management program including psychosocial support.

Diagnosis: Alcohol use disorder as defined by DSM-5
Treatment plan includes psychosocial support
Member is abstinent from alcohol at treatment initiation or documentation of prior detoxification and abstinence

Note

Provider Action — How to Request

Submit a complete prior authorization request including clinical rationale and supporting records to avoid delays. Include medication name, dose, duration, and specific reason for use (initiation, continuation, or restart after relapse).

Medication details: acamprosate calcium formulation, dose, frequency, planned start date
Indication: DSM-5 diagnosis of alcohol use disorder
Treatment intent: initiation vs continuation vs restart after relapse

Documentation Required

Required Documentation

Provide documentation that supports medical necessity for the requested drug. Include objective evidence of treatment response for continuation requests and evidence of abstinence when initiating therapy.

DSM-5 diagnostic documentation for alcohol use disorder
Evidence of abstinence at treatment initiation (e.g., clinical notes, toxicology when available)
Documentation of participation in a comprehensive management program with psychosocial support
For continuation: records showing positive clinical response (abstinence, increased abstinent days, fewer heavy drinking episodes, improved physical/psychosocial functioning)
If restarting after relapse: documentation of prior improvement on the therapy and reason for restart

Denial Risk

Denial Triggers & Risks

Requests that do not meet coverage criteria are at high risk for denial. Missing documentation of DSM-5 diagnosis, lack of evidence of abstinence at treatment initiation, or failure to show participation in psychosocial support are common denial reasons.

No DSM-5 diagnosis of alcohol use disorder documented
No evidence the member is abstinent at treatment initiation or failed detoxification prior to starting therapy
No documentation of a comprehensive management program including psychosocial support
Lack of demonstrated clinical benefit for continuation requests (no improvement in abstinence or related outcomes)

Background

Acamprosate calcium delayed‑release tablets are FDA‑approved for maintenance of abstinence from alcohol in patients with alcohol dependence who are already abstinent at treatment initiation. The product labeling emphasizes that acamprosate’s role is to support continued abstinence rather than to induce detoxification.

The FDA guidance further notes limitations in the evidence base: efficacy has not been demonstrated for patients who have not completed detoxification or who are not abstinent when treatment begins, and evidence is inadequate in polysubstance abusers. Because of these considerations, the policy aligns coverage with the FDA indication and requires integration with psychosocial support.

OpenPayer

Acamprosate prior authorization for alcohol use disorder

Coverage Criteria

Coding

Provider Actions & Authorization

Background

Definitions

Treatment Modalities